Towards a Brucella vaccine for humans

被引：166
作者：
Perkins, Stuart D. [1 ]
Smither, Sophie J. [1 ]
Atkins, Helen S. [1 ]
机构：
[1] Def Sci & Technol Lab, Dept Biomed Sci, Salisbury SP4 0JQ, Wilts, England
来源：
FEMS MICROBIOLOGY REVIEWS | 2010年 / 34卷 / 03期
关键词：
brucellosis; Brucella; vaccine; human; ZN SUPEROXIDE-DISMUTASE; PROTEIN CONFERS PROTECTION; OUTER-MEMBRANE PROTEIN-31; RIBOSOMAL L7/L12 PROTEIN; WILD-TYPE CHALLENGE; DNA VACCINE; BALB/C MICE; ABORTUS INFECTION; IMMUNE-RESPONSE; MELITENSIS INFECTION;
D O I：
10.1111/j.1574-6976.2010.00211.x
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
There is currently no licensed vaccine for brucellosis in humans. Available animal vaccines may cause disease and are considered unsuitable for use in humans. However, the causative pathogen, Brucella, is among the most common causes of laboratory-acquired infections and is a Center for Disease Control category B select agent. Thus, human vaccines for brucellosis are required. This review highlights the considerations that are needed in the journey to develop a human vaccine, including animal models, and includes an assessment of the current status of novel vaccine candidates.
引用
收藏
页码：379 / 394
页数：16
相关论文
共 130 条
  • [1] Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen
    Al-Mariri, A
    Tibor, A
    Lestrate, P
    Mertens, P
    De Bolle, X
    Letesson, JJ
    [J]. INFECTION AND IMMUNITY, 2002, 70 (04) : 1915 - 1923
  • [2] Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant
    Al-Mariri, A
    Tibor, A
    Mertens, P
    De Bolle, X
    Michel, P
    Godefroid, J
    Walravens, K
    Letesson, JJ
    [J]. INFECTION AND IMMUNITY, 2001, 69 (08) : 4816 - 4822
  • [3] Therapeutic options for human brucellosis
    Al-Tawfiq, Jaffar A.
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2008, 6 (01) : 109 - 120
  • [4] Transposon-derived Brucella abortus rough mutants are attenuated and exhibit reduced intracellular survival
    Allen, CA
    Adams, LG
    Ficht, TA
    [J]. INFECTION AND IMMUNITY, 1998, 66 (03) : 1008 - 1016
  • [5] Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide-dismutase:: II.: Induction of specific CD8+ cytotoxic lymphocytes and sensitized CD4+ IFN-γ-producing cell
    Andrews, Edilia
    Salgado, Paulina
    Folch, Hugo
    Onate, Angel
    [J]. MICROBIOLOGY AND IMMUNOLOGY, 2006, 50 (05) : 389 - 393
  • [6] ARAYA LN, 1989, J IMMUNOL, V143, P3330
  • [7] The Brucella abortus S19 ΔvjbR Live Vaccine Candidate Is Safer than S19 and Confers Protection against Wild-Type Challenge in BALB/c Mice When Delivered in a Sustained-Release Vehicle
    Arenas-Gamboa, A. M.
    Ficht, T. A.
    Kahl-McDonagh, M. M.
    Gomez, G.
    Rice-Ficht, A. C.
    [J]. INFECTION AND IMMUNITY, 2009, 77 (02) : 877 - 884
  • [8] Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge
    Arenas-Gamboa, Angela M.
    Ficht, Thomas A.
    Kahl-McDonagh, Melissa M.
    Rice-Ficht, Allison C.
    [J]. INFECTION AND IMMUNITY, 2008, 76 (06) : 2448 - 2455
  • [9] Identification of a candidate vaccine peptide on the 37 kDa Schistosoma mansoni GAPDH
    Argiro, L
    Kohlstädt, S
    Henri, S
    Dessein, H
    Matabiau, V
    Paris, P
    Bourgois, A
    Dessein, AJ
    [J]. VACCINE, 2000, 18 (19) : 2039 - 2048
  • [10] TREATMENT OF HUMAN BRUCELLOSIS WITH DOXYCYCLINE PLUS RIFAMPIN OR DOXYCYCLINE PLUS STREPTOMYCIN - A RANDOMIZED, DOUBLE-BLIND-STUDY
    ARIZA, J
    GUDIOL, F
    PALLARES, R
    VILADRICH, PF
    RUFI, G
    CORREDOIRA, J
    MIRAVITLLES, MR
    [J]. ANNALS OF INTERNAL MEDICINE, 1992, 117 (01) : 25 - 30
12345678910